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ABSTRACT
Objectives: Consistent estimation of the burden of
chronic obstructive pulmonary disease (COPD) has
been hindered by differences in methods, including
different spirometric cut-offs for impaired lung
function. The impact of different definitions on the
prevalence of potential airflow obstruction, and its
associations with key risk factors, is evaluated using
cross-sectional data from two nationally representative
population surveys.
Design: Pooled cross-sectional analysis of Wave 2 of
the UK Household Longitudinal Survey and the Health
Survey for England 2010, including 7879 participants,
aged 40–95 years, who lived in England and Wales,
without diagnosed asthma and with good-quality
spirometry data. Potential airflow obstruction was
defined using self-reported physician-diagnosed COPD;
a fixed threshold (FT) forced expiratory volume in
1 s/forced vital capacity (FEV1/FVC) ratio <0.7 and an
age-specific, sex-specific, height-specific and ethnic-
specific lower limit of normal (LLN). Standardised
questions elicited self-reported information on
demography, smoking history, ethnicity, occupation,
respiratory symptoms and cardiovascular disease.
Results: Consistent across definitions, participants
classed with obstructed airflow were more likely to be
older, currently smoke, have higher pack-years of
smoking and be engaged in routine occupations. The
prevalence of airflow obstruction was 2.8% (95% CI
2.3% to 3.2%), 22.2% (21.2% to 23.2%) and 13.1%
(12.2% to 13.9%) according to diagnosed COPD, FT and
LLN, respectively. The gap in prevalence between FT and
LLN increased in older age groups. Sex differences in the
risk of obstruction, after adjustment for key risk factors,
was sensitive to the choice of spirometric cut-off, being
significantly higher in men when using FT, compared
with no significant difference using LLN.
Conclusions: Applying FT or LLN spirometric cut-offs
gives a different picture of the size and distribution of
the disease burden. Longitudinal studies examining
differences in unscheduled hospital admissions and
risk of death between FT and LLN may inform the
choice as to the best way to include spirometry in
assessments of airflow obstruction.
INTRODUCTION
Chronic obstructive pulmonary disease
(COPD) is characterised by a progressive
decline in lung function.1 2 In total, 2.9
million deaths were attributed to COPD in
2010, making it the third leading global
cause of death.3 The National Outcomes
Strategy for COPD estimated that 835 000
people living in the UK are currently diag-
nosed with COPD, with a further 2.2 million
being undiagnosed.4 COPD is the second
leading cause of emergency hospital admis-
sion and is one of the most costly diseases in
terms of acute hospital care in England.4
Healthcare budgeting is often contingent
on the estimated burden of disease.
Spirometry, the mainstay of lung function
assessment, has been used in nationally rep-
resentative surveys to estimate the COPD
burden in terms of prevalence, associated
Strengths and limitations of this study
▪ Estimates of the burden of chronic obstructive
pulmonary disease using spirometry data col-
lected in epidemiological studies are inconsistent
through differences in methods, including differ-
ent spirometric cut-offs.
▪ Our study combined two nationally representative
samples of adults living in England and Wales,
with standardised protocols and objective mea-
surements of lung function, and a wide range of
clinically relevant conditions including self-
reported respiratory symptoms (chronic cough
and phlegm) and breathlessness.
▪ Consistent definitions and up-to-date reference
equations were used, providing baseline data for
monitoring purposes in the UK, and for facilitat-
ing comparison with international studies.
▪ Prevalence estimates were based on prebroncho-
dilator lung function measurements, and so are
likely to overestimate true prevalence.
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comorbidities and mortality. Estimation of the disease
burden has been hindered, however, by differences in
methods, including spirometric cut-offs.5–8 Fixed thresh-
olds (FTs) use cut-offs for lung function measurements
(eg, forced expiratory volume in 1 s/forced vital capacity
(FEV1/FVC) ratio <0.7) regardless of age, sex, height
and ethnicity.9 An additional threshold for per
cent-of-predicted FEV1 (expected for persons of a given
age, sex, height and ethnicity) is also commonly used
for severity classiﬁcation. In contrast, a lower limit of
normal (LLN) cut-off uses a statistical deﬁnition of
abnormal/normal (eg, below/above the lower 5th
centile of the distribution of age-speciﬁc, sex-speciﬁc,
height-speciﬁc and ethnic-speciﬁc FEV1/FVC values
from a healthy, lifelong non-smoking population).10
At present, applying FTs such as FEV1/FVC <0.7 is the
standard approach. However, the European Respiratory
Society (ERS) Task Force on epidemiology recently advo-
cated using the LLN in epidemiological studies as FTs
overestimate airﬂow obstruction in older populations,
due to the physiological reduction of FEV1/FVC with
age, and underestimate in young adults, compared with
LLN.11–16 The controversy over FT versus LLN thresh-
olds is well known with no signs of a consensus among
expert groups being agreed.17–21
Partly as a result of this controversy, the COPD epi-
demiological database shows heterogeneity in deﬁnitions
and consequential estimates of the disease burden.5 22
Two nationally representative samples, Wave 2 (2010–
2012) of the UK Household Longitudinal Survey
(UKHLS, ‘Understanding Society’) and the Health
Survey for England (HSE) 2010, collected lung function
data using identical measurement protocols and special-
ist equipment, providing an opportunity to increase stat-
istical precision by combining both data sets. Therefore,
the primary objective of the present study was to
compare the prevalence of ‘potential’ airﬂow obstruc-
tion according to FT and LLN thresholds among
persons aged 40–95 years living in England and Wales:
potential in the sense that the administration of bronch-
odilators to measure the extent of reversibility in airﬂow
obstruction was not used. As a secondary aim, we com-
pared the sensitivity of associations with risk factors
including age, sex, smoking history and socioeconomic
position. Using the same variables, we also examined the
characteristics associated with spirometry in connection
with self-reported physician-diagnosed COPD.
METHODOLOGY
Study design and setting
The UKHLS and HSE selected participants using strati-
ﬁed multistage probability sampling designs.23
Self-reported health information, risk factors and demo-
graphics were collected through face-to-face interviews,
followed by a visit from a trained nurse during which
lung function was measured. Response rates for the Wave
2 interview (among individuals issued) and nurse visit
(among eligible participants in the Wave 2 interview)
were 61% and 59%, respectively, in UKHLS. In HSE
2010, interview (among the estimated total number of
adults in sampled households) and nurse-visit (adults in
co-operating households) response rates were 59% and
57%. Sampling methods are described elsewhere.24–26
Eligible participants gave written consent to participate
in spirometry.
Questionnaire and procedures
Participants were excluded from spirometry for the fol-
lowing safety reasons: pregnancy; had in the past
3 months abdominal/chest surgery, a heart attack,
detached retina or eye or ear surgery; admitted to hos-
pital with a heart complaint in the preceding month; a
resting pulse rate >120 bpm or currently taking medica-
tions for the treatment of tuberculosis. Spirometry,
without bronchodilator use, was conducted using NDD
EasyOne PCC spirometers (NDD Medical Technologies,
Zurich, Switzerland). Quality control was summarised in
a session grade based on the number of technically
acceptable blows and their reproducibility. Grades A
(three acceptable manoeuvres, two highest FVC and
FEV1 within 100 mL), B (three acceptable manoeuvres,
two highest FVC and FEV1 within 150 mL) and C (two
or three acceptable manoeuvres within 200 mL) were
considered good quality. Full details on measurement
procedures are available elsewhere.25–27
The highest values for FEV1 and for FVC, from at least
three and up to eight blows, were used. Age-speciﬁc, sex-
speciﬁc, height-speciﬁc and ethnic-speciﬁc predicted
values and z-scores (FEV1, FVC and FEV1/FVC) were
computed using the ERS Global Lungs Initiative (GLI
2012, http://www.lungfunction.org) reference equa-
tions. These have been prepared by an international col-
laboration based on data spanning 26 countries from
>70 000 healthy individuals across four ethnic groups
(Caucasian, African-American, and North-East Asian
and South-East Asian), valid for persons aged 3–95
years28 29 and have been shown to ﬁt contemporary
Australasian spirometric data.30
FT and LLN spirometric cut-offs
Using FTs, we applied the 2007 Global Initiative for
Chronic Obstructive Lung Disease (GOLD) classiﬁca-
tion,31 which was designed for use with postbronchodila-
tor spirometry: potential airﬂow obstruction was deﬁned
as FEV1/FVC <0.7 (FT). Disease stage was deﬁned by
the reduction in FEV1 relative to per cent-of-predicted
values as follows: stage I (FEV1/FVC <0.7 and FEV1
≥80% of predicted); stage II (FEV1/FVC <0.7 and FEV1
50–79% of predicted) and stage III+ (FEV1/FVC <0.7
and FEV1 <50% of predicted).
32 Participants with
FEV1/FVC ≥0.7 were deﬁned as non-obstructed.
Participants with FEV1/FVC<LLN (below the lower
5th centile of the distribution of z-scores) were deﬁned
as obstructed (LLN). To examine possible heterogeneity
among participants with FEV1/FVC<LLN, disease stage
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was deﬁned by FEV1 relative to LLN as follows: stage I
(FEV1/FVC<LLN and FEV1≥LLN) and stage II
(FEV1/FVC<LLN and FEV1<LLN).
33 Participants with
FEV1/FVC≥LLN were deﬁned as non-obstructed. The
ﬁfth centile was chosen due to its established associa-
tions with respiratory symptoms and all-cause mortality.34
Physician-diagnosed COPD
In UKHLS, disease status was ascertained through ques-
tions asking “Has a doctor or other health professional
ever told you that you have [disease]?” Diagnosed COPD
was deﬁned as a positive response to either chronic
bronchitis or emphysema. In HSE, diagnosed COPD was
deﬁned as a positive response to the question “Did a
doctor ever tell you that you had chronic bronchitis,
emphysema or COPD?”
Risk factors, measurements of lung function and
comorbidities
Key subgroups were deﬁned by age (40–54, 55–64,
65–74, 75–95); sex; smoking status (current, former,
never); pack-years of cigarette smoking (a cumulative
total reﬂecting the amount and duration of consump-
tion, with 1 pack-year equating to an average of 20 cigar-
ettes smoked/day for 1 year) and socioeconomic
position, deﬁned by the National Statistics Socio-
Economic Classiﬁcation (NS-SEC), grouped into profes-
sional, intermediate and routine occupations.
FEV1, FVC and FEV1/FVC, on a continuous scale,
were expressed as per cent-of-predicted values.
Additional variables included current use of respiratory
medicine; area of residence (urban/rural); body mass
index (weight in kilograms divided by the square of
height in metres), grouped into normal weight (18.5–
24.9 kg/m2), overweight (25–29.9 kg/m2) and obese
(≥30 kg/m2); diagnosed diabetes; poor self-rated health
and reported cardiovascular disease (stroke, angina,
myocardial infarction). In HSE, participants were asked
to name any long-standing illness: respiratory diseases
were identiﬁed using International Classiﬁcation of Diseases,
Tenth Revision codes J00-J99. In the HSE, presence of
respiratory symptoms was deﬁned as usually coughing
ﬁrst thing in the morning, for at least 3 months/year,
and bringing up phlegm from the chest most days for
three consecutive months in a year. In the HSE, partici-
pants with some limitation of activity due to breathless-
ness during daily living were identiﬁed by a score of 3+
on the Medical Research Council (MRC) dyspnoea
scale. Exposure to passive smoking in the HSE was mea-
sured by reported number of hours/week currently
exposed to cigarette smoke (0, 1–9 and ≥10 h).
Statistical analyses
A lower age limit was used of 40 years due to the low
prevalence of non-asthma airﬂow obstruction in the
youngest age groups.35 As bronchodilators were not
used, we excluded participants who reported diagnosed
asthma.34 36–38 Five sets of analyses were conducted
across the categories of diagnosed COPD, FT and LLN.
First, participants’ characteristics (demographics, risk
factors, comorbidities and per cent-of-predicted FEV1,
FVC and FEV1/FVC) were summarised as means, accom-
panied by SD, or as counts accompanied by percentages.
Participants were counted under each relevant deﬁn-
ition. Participants with/without obstruction were com-
pared using the χ2 test and analysis of variance for
categorical and continuous variables, respectively.39
Second, prevalence estimates were computed for a
subset of sociodemographic variables deﬁned by age,
sex, smoking status, pack-years of cigarette smoking and
NS-SEC. Third, in the absence of a gold standard, we
calculated the sensitivity and speciﬁcity of each spiro-
metric criterion, using the alternative cut-off as the refer-
ence standard.40
Fourth, regression analyses were performed using age,
sex, pack-years of smoking and NS-SEC as independent
variables with airﬂow obstruction as outcome. Current
smoking status could not be entered in the same model
as pack-years due to signiﬁcant collinearity. The depend-
ent variable based on FTs had four categories: non-
obstructed, stage I, stage II and stage III+. The
LLN-derived outcome had three categories: non-
obstructed, stage I and stage II. In each case, multi-
nomial logistic regression was used to estimate relative
risk ratios (RRRs), with non-obstructed as the reference
category. Multinomial logistic regression generalises
logistic regression to outcomes with more than two pos-
sible discrete outcomes. The RRR is interpreted as the
relative risk of one outcome in relation to the reference
category for a speciﬁed category of an independent vari-
able compared with the reference.41 42 Diagnosed
COPD was analysed as a binary outcome (not reported/
reported): logistic regression was therefore used to esti-
mate ORs.39 41 The overall association for independent
variables with >2 categories was computed using the
adjusted Wald test. The likelihood ratio test was used to
estimate the statistical signiﬁcance of interaction terms:
non-signiﬁcant terms were excluded, and models reﬁt-
ted with only the main effects.
Fifth, to examine risk factors associated with possible
underdiagnosis, a four-category outcome variable was
created combining diagnosed COPD and spirometric
criteria as follows: (1) neither diagnosed nor spirometri-
cally deﬁned obstruction; (2) physician-diagnosed
COPD but no obstructive spirometry; (3) spirometrically
deﬁned but no diagnosed COPD and (4) both diag-
nosed and obstructive spirometry.43 FT and LLN cut-offs
were analysed separately. RRRs generated from multi-
nomial logistic regressions were used to examine associa-
tions between the same set of risk factors listed above
and the composite dependent variable.
Participants with missing values on covariates were
excluded from relevant analyses. Tests of statistical sig-
niﬁcance were based on two-sided probability (p<0.05).
Data set preparation was performed in SPSS V.20.0
(SPSS IBM Inc, Chicago, Illinois, USA), Stata V.13.1
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(StataCorp, College Station, Texas, USA) and R (V.3.0.3;
R Foundation, http://www.r-project.org). Analysis was
conducted in Stata accounting for the complex design
of both surveys, using the appropriate weighting vari-
ables and primary sampling units. Both datasets are
available via the UK Data Service (http://www.
ukdataservice.ac.uk).
Sensitivity analyses
Analyses were initially undertaken excluding participants
with reported diagnosed asthma and then repeated
including those with asthma. In accordance with the pre-
vious UK National Institute for Health and Care
Excellence (NICE) recommendations,44 comparisons
between FT and LLN were rerun deﬁning only the
subset of FT participants with FEV1 <80% of predicted
(ie, stage II+) as having obstructed airﬂow.
RESULTS
The analytical sample comprised 7879 participants
(5936 and 1943 from UKHLS and HSE, respectively)
aged 40–95 years, who resided in England and Wales,
did not report diagnosed asthma, had valid values of
height and ethnicity and provided good-quality spirom-
etry. Response ﬂow charts for the UKHLS and HSE are
provided in online supplementary ﬁgures S1 and S2,
respectively. Excluded participants were more likely to
be older, engaged in routine occupations and self-
reported respiratory symptoms (data not shown).
Differences between the UKHLS and HSE in terms of
sex ratio, age, smoking history, NS-SEC and objective
measurements of lung function were not materially
important (see online supplementary table S1).
Descriptive characteristics of the analytical sample
according to physician-diagnosed COPD, FTand LLN are
shown in online supplementary tables S2 and S3. Overall,
46.8% of participants were men, with mean age
57.6 years (SD 12.3), 16.6% were current smokers, 4.6%
had >50 pack-years of cigarette smoking and 36.5% were
engaged in professional occupations. Twelve (0.1%) and
265 (3.2%) participants had missing values for pack-years
and NS-SEC, respectively. The prevalence of diagnosed
COPD was similar between the sexes (p=0.349), but was
higher for men using FT and LLN (both p<0.001).
Participants with diagnosed COPD/obstructive spirom-
etry were more likely to be older, currently smoke, have
higher pack-years of smoking and be engaged in routine
occupations (all p<0.001). Prevalence of diagnosed
COPD was higher in HSE versus UKHLS (p<0.001), but
survey-speciﬁc prevalence was similar for FTand for LLN.
Participants with diagnosed COPD/obstructive spiro-
metry were more likely to report respiratory symptoms
(chronic cough and phlegm) and disease, current use of
respiratory medications, cardiovascular disease, breath-
lessness, poor self-rated health and have, on average,
lower (per cent-of-predicted) values of FEV1, FVC and
FEV1/FVC. The prevalence of respiratory symptoms was
13.7%, 10.2% and 11.3% among participants classed as
having airﬂow obstruction according to diagnosed
COPD, FT and LLN, respectively; prevalence of having a
score of 3+ on the MRC dyspnoea scale was 34.8%, 12.3%
and 15.9%.
Prevalence of airflow obstruction
The prevalence of airﬂow obstruction was 2.8%, 22.2%
and 13.1% using diagnosed COPD, FT and LLN, respect-
ively (table 1). Using FTs, 11.6%, 8.9% and 1.7% of parti-
cipants were classed as stage I, stage II and stage III+,
respectively. LLN-derived obstruction was 6.6% (stage I)
and 6.4% (stage II). For most subgroups, prevalence was
highest for FT and lowest for diagnosed COPD, with LLN
falling in between. The gap in prevalence between FT
and LLN increased in older age groups. Prevalence
among participants aged 40–54 years was 11.9% and
10.7% using FT and LLN, respectively. Prevalence among
participants aged 75–95 was 45% and 17.2%.
Table 2 shows estimates of sensitivity and speciﬁcity for
FT and LLN, using the alternative spirometric cut-off as
the reference standard. When using LLN as reference,
speciﬁcity—the percentage of participants classed as
non-obstructed using LLN identiﬁed as non-obstructed
using FT—decreased from 94.9% among participants
aged 40–64 years to 74.4% among those aged 65–95.
Multivariate analyses of airflow obstruction
Table 3 shows the signiﬁcant risk factors for diagnosed
COPD, and the FT and LLN disease stage classiﬁcations
(non-obstructed as reference category). For diagnosed
COPD, the signiﬁcant interaction between sex and age
group (p=0.022) suggested no difference in odds
between the sexes among participants aged 40–64 years,
but higher odds among men aged 65–95. Using FTs,
being male was associated with a signiﬁcantly increased
risk of airﬂow obstruction: RRR 1.35 (95% CI 1.16 to
1.58), RRR 1.35 (1.12 to 1.63) and RRR 1.72 (1.08 to
2.76) for stages I, II and III+, respectively. In contrast,
sex differences were not signiﬁcant using LLN: RRR
1.07 (0.88 to 1.31) for stage I and RRR 1.20 (0.96 to
1.50) for stage II.
Odds of diagnosed COPD increased signiﬁcantly with
age only in men (p=0.022 for the interaction term).
Using non-obstruction as reference, RRRs increased sig-
niﬁcantly with age when using FTs (p<0.001 for each
stage). The age-related difference using LLN was more
marked for stage II (p=0.492 and p<0.001 for stages I
and II, respectively). A dose-related increased risk with
pack-years of cigarette smoking was observed across each
deﬁnition (p<0.001). The difference between NS-SEC
levels was more marked with diagnosed COPD
(p=0.012) and the tightest FT and LLN deﬁnitions (FT:
p=0.002 stage III+; LLN: p<0.001 stage II).
Combination of diagnosed COPD and spirometric cut-offs
The signiﬁcant risk factors for the two four-category
outcome variables created as a composite of diagnosed
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Table 1 Prevalence of diagnosed COPD and potential airflow obstruction using FTs and LLN spirometric criteria, persons aged 40–95 years without diagnosed asthma, HSE 2010
and UKHLS Wave 2 (2010–2012)*
Diagnosed-
COPD†
FTs‡ LLN§
Obstructed Stage I Stage II Stage III+ Obstructed Stage I Stage II
n % (95% CI) % (95% CI) % (95% CI) % (95% CI) % (95% CI) % (95% CI) % (95% CI) % (95% CI)
All 7879 2.8 (2.3 to 3.2) 22.2 (21.2 to 23.2) 11.6 (10.9 to 12.4) 8.9 (8.2 to 9.6) 1.7 (1.3 to 2.0) 13.1 (12.2 to 13.9) 6.6 (6.0 to 7.3) 6.4 (5.8 to 7.0)
Sex
Males 3335 3.0 (2.3 to 3.6) 26.3 (24.8 to 27.9) 13.2 (12.1 to 14.4) 10.7 (9.6 to 11.8) 2.4 (1.8 to 3.0) 15.0 (13.7 to 16.4) 7.2 (6.2 to 8.1) 7.9 (6.9 to 8.9)
Females 4544 2.6 (2.0 to 3.1) 18.6 (17.4 to 19.9) 10.2 (9.2 to 11.2) 7.4 (6.5 to 8.2) 1.0 (0.7 to 1.4) 11.3 (10.3 to 12.3) 6.2 (5.4 to 6.9) 5.1 (4.4 to 5.9)
Age group
40–54 3472 1.7 (1.3 to 2.2) 11.9 (10.7 to 13.1) 7.0 (6.1 to 7.9) 4.6 (3.8 to 5.4) 0.3 (0.1 to 0.6) 10.7 (9.6 to 11.9) 6.7 (5.7 to 7.6) 4.1 (3.3 to 4.9)
55–64 2072 3.4 (2.5 to 4.2) 24.2 (22.2 to 26.1) 12.6 (11.1 to 14.1) 9.5 (8.1 to 10.9) 2.0 (1.4 to 2.7) 14.2 (12.6 to 15.8) 6.5 (5.4 to 7.7) 7.7 (6.4 to 8.9)
65–74 1557 3.9 (2.8 to 5.0) 32.6 (30.1 to 35.1) 16.5 (14.6 to 18.5) 12.9 (11.1 to 14.6) 3.2 (2.1 to 4.2) 15.0 (13.0 to 17.0) 6.4 (5.1 to 7.7) 8.6 (7.0 to 10.2)
75–95 778 3.9 (2.0 to 5.8) 45.0 (41.1 to 48.8) 21.1 (18.0 to 24.2) 19.6 (16.6 to 22.6) 4.3 (2.5 to 6.0) 17.2 (14.2 to 20.1) 7.2 (5.2 to 9.2) 9.9 (7.6 to 12.3)
Smoking status
Current 1198 4.7 (3.5 to 6.0) 37.0 (34.1 to 39.9) 14.5 (12.3 to 16.6) 18.2 (15.9 to 20.6) 4.2 (3.0 to 5.4) 29.8 (27.0 to 32.6) 13.5 (11.3 to 15.7) 16.2 (14.0 to 18.5)
Ex-regular 2547 3.6 (2.7 to 4.5) 26.8 (24.9 to 28.7) 14.1 (12.7 to 15.6) 10.5 (9.2 to 11.8) 2.2 (1.5 to 2.9) 14.5 (13.0 to 16.1) 7.2 (6.0 to 8.3) 7.4 (6.2 to 8.5)
Never 4134 1.6 (1.2 to 2.0) 14.7 (13.5 to 15.9) 9.2 (8.2 to 10.1) 5.0 (4.3 to 5.7) 0.5 (0.2 to 0.9) 6.8 (5.9 to 7.7) 4.1 (3.5 to 4.8) 2.7 (2.1 to 3.3)
Pack-years¶
0–0.9 4299 1.6 (1.2 to 2.0) 14.8 (13.6 to 16.0) 9.3 (8.4 to 10.3) 5.0 (4.3 to 5.7) 0.5 (0.2 to 0.8) 6.7 (5.9 to 7.6) 4.1 (3.5 to 4.7) 2.6 (2.0 to 3.2)
1–19.9 1905 2.3 (1.5 to 3.1) 22.3 (20.3 to 24.3) 12.9 (11.3 to 14.5) 7.5 (6.2 to 8.8) 1.9 (1.1 to 2.6) 13.4 (11.7 to 15.1) 7.6 (6.3 to 8.9) 5.8 (4.6 to 7.0)
20–49.9 1318 5.0 (3.6 to 6.5) 36.8 (34.0 to 39.6) 15.7 (13.5 to 17.9) 18.1 (15.9 to 20.4) 2.9 (2.0 to 3.9) 25.4 (22.8 to 27.9) 11.6 (9.5 to 13.6) 13.8 (11.8 to 15.8)
50+ 345 10.5 (7.0 to 14.1) 53.7 (48.0 to 59.4) 16.0 (12.0 to 20.1) 28.0 (23.0 to 32.9) 9.7 (6.2 to 13.2) 39.3 (33.5 to 45.0) 12.4 (8.7 to 16.2) 26.9 (21.6 to 32.1)
NS-SEC¶
Professional 3050 1.9 (1.4 to 2.4) 17.1 (15.7 to 18.5) 10.4 (9.3 to 11.6) 5.7 (4.9 to 6.5) 1.0 (0.6 to 1.4) 9.1 (8.0 to 10.2) 5.6 (4.6 to 6.5) 3.6 (2.9 to 4.3)
Intermediate 1859 2.3 (1.6 to 3.0) 21.9 (19.9 to 23.9) 12.5 (10.9 to 14.1) 8.4 (7.0 to 9.7) 1.1 (0.5 to 1.7) 12.0 (10.5 to 13.5) 6.6 (5.4 to 7.8) 5.4 (4.3 to 6.5)
Routine 2705 4.0 (3.1 to 4.8) 26.6 (24.7 to 28.5) 11.6 (10.3 to 12.9) 12.3 (10.9 to 13.7) 2.7 (2.0 to 3.5) 17.4 (15.8 to 19.1) 7.7 (6.6 to 8.9) 9.7 (8.4 to 11.0)
*Participants were included under each relevant definition. Bronchodilators were not used. Cell counts are unweighted; prevalence estimates were weighted.
†HSE: reported diagnosed COPD, bronchitis or emphysema; UKHLS: diagnosed bronchitis or emphysema.
‡FTs: obstruction (FT): FEV1/FVC <0.7. Staging classification: stage I (FEV1/FVC <0.7 and FEV1 ≥80% of predicted); stage II (FEV1/FVC <0.7 and FEV1 50–79% of predicted); stage III+
(FEV1/FVC <0.7 and FEV1 <50% of predicted).
§LLN: obstruction (LLN): FEV1/FVC<LLN. Staging classification: stage I (FEV1/FVC<LLN and FEV1>LLN); stage II (FEV1/FVC<LLN and FEV1<LLN).
¶Missing data: 12/7879 (0.2%) pack-years of cigarette smoking; 265/7879 (3.4%) NS-SEC.
COPD, chronic obstructive pulmonary disease; FEV1, maximum expiratory volume in 1 s; FTs, fixed thresholds; FVC, forced vital capacity; HSE, Health Survey for England; LLN, lower limit of
normal (below the lower 5th centile of z-scores); NS-SEC, National Statistics Socio-Economic Classification; UKHLS, UK Household Longitudinal Survey.
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COPD and obstructive spirometry are shown in table 4.
Relative to the reference category (neither doctor-
diagnosed nor spirometrically deﬁned airﬂow obstruc-
tion), the risk of reporting COPD in the absence of
obstructive spirometry was signiﬁcantly lower in men
using either spirometric criterion (FT: RRR 0.53 (95%
CI 0.32 to 0.87); LLN: RRR 0.56 (0.35 to 0.89)). The
risk of having obstructed airﬂow using spirometry but
with no diagnosed COPD—thereby indicating possible
underdiagnosis—was signiﬁcantly higher in men, and in
older age groups, when using FT but not LLN. For both
spirometric criterions, increases in risk with increasing
pack-years of cigarette smoking, relative to the reference,
was consistent across combinations of COPD/obstructive
spirometry; the difference between NS-SEC levels was
more marked for obstructive spirometry.
Sensitivity analyses
Repeating analyses by including 1183 participants with
reported diagnosed asthma increased prevalence of
diagnosed COPD, FT and LLN by 2–3 percentage points
(see online supplementary ﬁgure S3), but showed
similar patterns of association with risk factors.
Diagnosed asthma was a strong predictor of diagnosed
COPD and obstructive spirometry (p<0.001, data not
shown). Narrowing FT-deﬁned obstruction to the subset
of FT participants with FEV1 <80% of predicted (ie,
stage II+) more than halved the FT-derived prevalence
(22.2% vs 10.6%). Among participants aged 65–95 years,
speciﬁcity using LLN as the reference standard was
74.4% and 91.1% for FT and FT stage II+, respectively
(table 2). Patterns of association with risk factors using
FT stage II+ were similar to those shown for FT.
DISCUSSION
Consistent estimation of the COPD burden has been
hindered by differences in methods, including disagree-
ment among experts over the choice of FT versus LLN
spirometric cut-offs.5–8 In this study, we combined two
nationally representative surveys, with standardised pro-
tocols and objective lung function measurements, to
evaluate the impact of different deﬁnitions on the preva-
lence of potential airﬂow obstruction, and its associa-
tions with key risk factors. Participants with diagnosed
COPD/obstructive spirometry were more likely to be
older, currently smoke, have higher pack-years of cigar-
ette smoking, be in lower socioeconomic groups and
report the presence of respiratory symptoms (chronic
cough and phlegm), cardiovascular disease, breathless-
ness and poor self-rated health. Among persons aged
40–95 years without physician-diagnosed asthma, preva-
lence was 2.8%, 22.2% and 13.1%, according to diag-
nosed COPD, FT and LLN, respectively. The gap in
prevalence between FT and LLN increased in older age
groups. When using LLN as the reference standard, spe-
ciﬁcity for FT decreased from 94.9% among participants
aged 40–64 years to 74.4% among participants aged 65–
95, corresponding to false-positive rates of 5.1% and
25.6%, respectively. Sex differences in the risk of
Table 2 Sensitivity and specificity of FTs and LLN spirometric criteria by age group, persons aged 40–95 years without
diagnosed asthma, Health Survey for England 2010 and UK Household Longitudinal Survey Wave 2 (2010–2012)
40–64 (n=5544) 65–95 (n=2335) 40–64 (n=5544) 65–95 (n=2335)
FT using LLN as reference standard LLN using FT as reference standard
False positives (%) 5.1 25.6 0.4 0.0
False negatives (%) 2.5 0.0 28.0 57.6
Sensitivity 0.975 1.000 0.720 0.424
Specificity 0.949 0.744 0.996 1.000
PPV 0.720 0.424 0.975 1.000
NPV 0.996 1.000 0.949 0.744
κ coefficient 0.801 0.479 0.801 0.479
Likelihood ratio positive 18.98 3.90 200.65 N/A
Likelihood ratio negative 0.027 0.000 0.281 0.576
FT (stage II+) using LLN as reference
standard
LLN using FT (stage II+) as reference
standard
False positives (%) 1.3 8.9 6.3 5.2
False negatives (%) 49.2 26.7 16.0 39.1
Sensitivity 0.508 0.733 0.840 0.609
Specificity 0.987 0.911 0.937 0.948
PPV 0.840 0.609 0.508 0.733
NPV 0.937 0.948 0.987 0.911
κ coefficient 0.597 0.596 0.597 0.596
Likelihood ratio positive 38.82 8.28 13.27 11.67
Likelihood ratio negative 0.499 0.292 0.170 0.412
FTs, fixed thresholds; LLN, lower limit of normal (below the 5th centile of z-scores); NPV, negative predictive value; PPV, positive predictive
value.
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Table 3 Results of logistic and multinomial logistic regressions for reported diagnosed COPD and potential airflow obstruction using FTs and LLN spirometric criteria among persons aged
40–95 years, HSE 2010 and UKHLS Wave 2 (2010–2012)*
Characteristics
FTs‡ LLN§
Non-obstructed as reference Non-obstructed as reference
Diagnosed-COPD† Stage I Stage II Stage III+ Stage I Stage II
N OR (95% CI) RRR (95% CI)¶ RRR (95% CI)¶ RRR (95% CI)¶ RRR (95% CI)¶ RRR (95% CI)¶
Sex
Females** 4372 1.00 1.00 1.00 1.00 1.00 1.00
Males 3231 0.60 (0.34 to 1.05) 1.35 (1.16 to 1.58) 1.35 (1.12 to 1.63) 1.72 (1.08 to 2.76) 1.07 (0.88 to 1.31) 1.20 (0.96 to 1.50)
p Value 0.075 <0.001 0.002 0.024 0.503 0.107
Age group
40–54** 3416 1.00 1.00 1.00 1.00 1.00 1.00
55–64 2022 1.66 (1.07 to 2.58) 2.00 (1.63 to 2.45) 2.13 (1.65 to 2.73) 6.05 (2.82 to 12.99) 0.92 (0.72 to 1.18) 1.57 (1.20 to 2.06)
65–74 1451 0.96 (0.54 to 1.70) 2.85 (2.30 to 3.53) 3.01 (2.32 to 3.89) 10.11 (4.55 to 22.49) 0.83 (0.63 to 1.09) 1.56 (1.16 to 2.12)
75+ 714 1.20 (0.39 to 3.70) 4.72 (3.66 to 6.07) 6.67 (5.00 to 8.90) 22.26 (9.45 to 52.44) 1.06 (0.74 to 1.51) 2.20 (1.52 to 3.17)
p Value 0.104 <0.001 <0.001 <0.001 0.492 <0.001
Pack-years††
0–0.9** 4165 1.00 1.00 1.00 1.00 1.00 1.00
1–19.9 1835 1.38 (0.88 to 2.17) 1.61 (1.34 to 1.93) 1.66 (1.29 to 2.15) 3.82 (1.80 to 8.14) 1.94 (1.51 to 2.49) 2.22 (1.58 to 3.12)
20–49.9 1269 2.91 (1.91 to 4.45) 2.30 (1.86 to 2.85) 4.56 (3.64 to 5.72) 5.91 (2.81 to 12.45) 3.39 (2.61 to 4.41) 5.43 (3.98 to 7.41)
50+ 334 5.64 (3.45 to 9.22) 2.34 (1.63 to 3.35) 6.83 (4.85 to 9.63) 17.27 (7.88 to 37.84) 4.50 (2.96 to 6.84) 11.20 (7.59 to 16.52)
p Value <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
NS-SEC††
Professional** 3047 1.00 1.00 1.00 1.00 1.00 1.00
Intermediate 1855 1.03 (0.68 to 1.58) 1.18 (0.97 to 1.45) 1.34 (1.04 to 1.72) 1.01 (0.51 to 2.00) 1.14 (0.88 to 1.48) 1.35 (0.99 to 1.85)
Routine 2701 1.61 (1.13 to 2.31) 1.07 (0.89 to 1.29) 1.82 (1.47 to 2.26) 2.30 (1.36 to 3.88) 1.28 (1.01 to 1.63) 2.18 (1.67 to 2.85)
p Value 0.012 0.246 <0.001 0.002 0.123 <0.001
Sample
UKHLS** 5675 1.00 1.00 1.00 1.00 1.00 1.00
HSE 1928 2.22 (1.60 to 3.07) 0.95 (0.79 to 1.14) 0.97 (0.79 to 1.20) 0.99 (0.62 to 1.59) 1.05 (0.82 to 1.33) 0.99 (0.77 to 1.26)
p Value <0.001 0.587 0.798 0.967 0.716 0.913
Males×age group
40–54¶ 1319 1.00 – – – – –
55–64 876 1.16 (0.54 to 2.45) – – – – –
65–74 664 3.21 (1.40 to 7.39) – – – – –
75+ 372 2.61 (0.67 to 10.22) – – – – –
p Value 0.022 – – – – –
*Participants were included under each relevant definition. Bronchodilators were not used. Cell counts are unweighted; ORs and RRRs estimated using survey weights.
†HSE: reported diagnosed COPD, bronchitis or emphysema; UKHLS: diagnosed bronchitis or emphysema.
‡FTs: stage I (FEV1/FVC <0.7 and FEV1 ≥80% of predicted); stage II (FEV1/FVC <0.7 and FEV1 50–79% of predicted); stage III+ (FEV1/FVC <0.7 and FEV1 <50% of predicted). Reference
category: FEV1/FVC ≥0.7.
§LLN: stage I (FEV1/FVC<LLN and FEV1>LLN); stage II (FEV1/FVC<LLN and FEV1<LLN). Reference category: FEV1/FVC≥LLN.
¶The RRR is interpreted as the relative risk of one outcome in relation to the reference category for a specified category of an independent variable compared with the reference category for that
independent variable. Using FT stage I as an example, the RRR for men versus women is interpreted as the relative risk for FT stage I versus non-obstruction for men compared with the
analogous relative risk for women, adjusted for the other variables in the model.
**Reference category.
††Missing data: 12/7879 (0.2%) pack-years of cigarette smoking; 265/7879 (3.4%) NS-SEC.
COPD, chronic obstructive pulmonary disease; FEV1, maximum expiratory volume in 1 s; FTs, fixed thresholds; FVC, forced vital capacity; HSE, Health Survey for England; LLN, lower limit of
normal (below the 5th centile of z-scores); NS-SEC, National Statistics Socio-Economic Classification; OR, odds ratio; RRR; relative risk ratios; UKHLS, UK Household Longitudinal Survey.
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Table 4 Results of multinomial logistic regressions for combined outcome variable based on diagnosed COPD and potential airflow obstruction using FTs and LLN
spirometric criteria among persons aged 40–95 years, HSE 2010 and UKHLS Wave 2 (2010–2012)*
Characteristics
FTs† LLN‡
Neither diagnosed nor obstructive spirometry as reference Neither diagnosed nor obstructive spirometry as reference
Diagnosed alone
Obstructive
spirometry alone
Diagnosed and
obstructive spirometry Diagnosed alone
Obstructive
spirometry alone
Diagnosed and
obstructive spirometry
n RRR (95% CI)§ RRR (95% CI)§ RRR (95% CI)§ RRR (95% CI)§ RRR (95% CI)§ RRR (95% CI)§
Sex
Females¶ 4372 1.00 1.00 1.00 1.00 1.00 1.00
Males 3231 0.49 (0.31 to 0.79) 1.31 (1.16 to 1.49) 2.23 (1.34 to 3.71) 0.52 (0.34 to 0.81) 1.05 (0.90 to 1.23) 2.15 (1.25 to 3.71)
p Value 0.003 <0.001 0.002 0.004 0.543 0.006
Age-group
40–54¶ 3416 1.00 1.00 1.00 1.00 1.00 1.00
55–64 2022 1.26 (0.76 to 2.09) 2.08 (1.76 to 2.46) 4.06 (2.11 to 7.79) 1.34 (0.83 to 2.16) 1.09 (0.90 to 1.33) 2.91 (1.49 to 5.68)
65–74 1451 1.47 (0.84 to 2.55) 3.05 (2.56 to 3.63) 4.78 (2.38 to 9.57) 1.27 (0.74 to 2.15) 1.02 (0.82 to 1.27) 3.12 (1.53 to 6.36)
75+ 714 1.95 (0.69 to 5.51) 5.89 (4.76 to 7.29) 7.55 (3.35 to 17.02) 1.60 (0.67 to 3.81) 1.42 (1.08 to 1.87) 3.47 (1.43 to 8.40)
p Value 0.388 <0.001 <0.001 0.535 0.085 <0.001
Pack-years**
0–0.9¶ 4165 1.00 1.00 1.00 1.00 1.00 1.00
1–19.9 1835 1.08 (0.61 to 1.92) 1.67 (1.42 to 1.96) 2.84 (1.30 to 6.23) 1.16 (0.68 to 2.00) 2.02 (1.63 to 2.50) 2.58 (1.10 to 6.01)
20–49.9 1269 3.05 (1.68 to 5.54) 3.18 (2.70 to 3.74) 6.70 (3.35 to 13.40) 2.98 (1.72 to 5.16) 4.23 (3.44 to 5.20) 5.74 (2.70 to 12.20)
50+ 334 3.94 (1.70 to 9.13) 4.15 (3.13 to 5.49) 18.50 (8.41 to 40.70) 3.87 (1.81 to 8.29) 6.83 (4.98 to 9.37) 17.23 (7.37 to 40.28)
p Value <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
NS-SEC**
Professional¶ 3047 1.00 1.00 1.00 1.00 1.00 1.00
Intermediate 1855 0.76 (0.45 to 1.30) 1.20 (1.02 to 1.41) 1.84 (0.87 to 3.87) 0.83 (0.50 to 1.40) 1.19 (0.97 to 1.47) 1.57 (0.72 to 3.44)
Routine 2701 0.93 (0.59 to 1.48) 1.31 (1.12 to 1.53) 3.65 (1.89 to 7.06) 1.08 (0.70 to 1.67) 1.54 (1.27 to 1.87) 3.37 (1.70 to 6.68)
p Value 0.612 0.002 <0.001 0.632 <0.001 <0.001
Sample
UKHLS¶ 5675 1.00 1.00 1.00 1.00 1.00 1.00
HSE 1928 2.38 (1.54 to 3.69) 0.94 (0.81 to 1.09) 1.92 (1.21 to 3.05) 2.21 (1.46 to 3.35) 0.96 (0.79 to 1.16) 2.13 (1.31 to 3.48)
p Value <0.001 0.420 0.006 <0.001 0.664 0.002
*Participants were included under each relevant definition. Bronchodilators were not used. Cell counts unweighted; RRRs estimated using survey weights.
†FTs: obstruction (FT): FEV1/FVC <0.7. Diagnosed COPD: HSE: reported diagnosed chronic bronchitis, emphysema, or COPD; UKHLS: diagnosed bronchitis or emphysema.
‡LLN: obstruction (LLN): FEV1/FVC<LLN. Diagnosed COPD: HSE: reported diagnosed chronic bronchitis, emphysema, or COPD; UKHLS: diagnosed bronchitis or emphysema.
§The RRR is interpreted as the relative risk of one outcome in relation to the reference category for a specified category of an independent variable compared with the reference category for that
independent variable. Using diagnosed alone as an example, the RRR for men versus women is interpreted as the relative risk for diagnosed alone versus neither diagnosed nor objective
spirometry for men compared with the analogous relative risk for women, adjusted for the other variables in the model.
¶Reference category.
**Missing data: 12/7879 (0.2%) pack-years of cigarette smoking; 265/7879 (3.4%) NS-SEC.
COPD, chronic obstructive pulmonary disease; FEV1, maximum expiratory volume in 1 s; FTs, fixed thresholds; FVC, forced vital capacity; HSE, Health Survey for England; LLN, lower limit of
normal (below the 5th centile of z-scores); NS-SEC, National Statistics Socio-Economic Classification; RRR; relative risk ratios; UKHLS, UK Household Longitudinal Survey.
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obstructed airﬂow, after adjustment for potential con-
founders, were sensitive to spirometric criteria, being
higher among men for FT, compared with no difference
using LLN.
Strengths and limitations
Analyses were based on nationally representative
samples, with identical measurement protocols and spe-
cialist equipment for collecting lung function data.
Combining the HSE and UKHLS data sets increased stat-
istical precision for spirometry-based estimates, particu-
larly for population subgroups, and allowed detailed
analyses to be conducted. Predicted values and z-scores
were obtained from the ERS GLI 2012 reference equa-
tions,28 facilitating inclusion of older participants, non-
white populations and comparability with international
studies. Our study has a number of limitations.
Reversibility in airﬂow obstruction could not be assessed
due to bronchodilators not being used. Spirometry-
based prevalence, therefore, may be overestimated.
Analysis of the National Health and Nutrition
Examination Survey (NHANES) 2007–2010 showed that
FT and LLN prevalence estimates among US adults aged
40–79 years decreased, in relative terms, by approxi-
mately one-third after administration of bronchodila-
tors.45 Although recent guidelines from NICE46 and
ERS13 recommend use of postbronchodilator spirometry
to conﬁrm the presence of airﬂow obstruction, debate
continues over its use in epidemiological settings, with
the arguments against including ethical issues such as
possible side effects and contraindications.47 Potential
misclassiﬁcation of disease status through bronchodila-
tors not being used was reduced by excluding partici-
pants with physician-diagnosed asthma. Some
participants in the analytical sample, however, may be
undiagnosed asthmatics. On the other hand, the disease
burden may be underestimated through excluding parti-
cipants with poor-quality spirometry. Participation in
spirometry, and achievement of good-quality standards
among participants with any spirometry data, was higher
among participants of younger age, engaged in profes-
sional/managerial occupations, non-smokers and with
no physician-diagnosed COPD. Lower survey participa-
tion rates among sociodemographic groups at higher
risk of airﬂow obstruction (eg, older persons, lower
socioeconomic groups) would also have led to an under-
estimation of true prevalence. These limitations,
however, are unlikely to affect comparisons across deﬁni-
tions, but may have led to an underestimate of risk asso-
ciations. The list of health conditions in the UKHLS
interview programme included chronic bronchitis and
emphysema but not COPD, leading to potential under-
estimation of self-reported physician-diagnosed COPD.
Comparisons with previous studies
Earlier analyses of HSE data36 38 48 used older reference
equations49 50 applicable only to white, younger popula-
tions. Nevertheless, estimates of prevalence and their
substantive conclusions of higher prevalence using FT
versus LLN, with a widening gap in prevalence in older
age groups, and sex differences when using FT but not
LLN were similar to ours: conﬁrming ﬁndings reported
in the USA,45 Europe,51 Korea,16 internationally,12 and
in recent literature reviews.6 52 A further strength of our
study was the wide range of clinically relevant conditions
examined in the context of disease staging, with higher
prevalence of respiratory symptoms, respiratory and car-
diovascular diseases, breathlessness and poor self-rated
health among participants in the tightest deﬁnitions of
FT and LLN obstruction, conﬁrming similar ﬁndings in
the USA.53 54 While recent guidelines13 46 55 recom-
mend adopting multidimensional deﬁnitions of respira-
tory disease, our study outcomes were deﬁned only
using spirometry. While we acknowledge the merits of a
multidimensional approach, and agree that neither
spirometric cut-off is able to fully characterise the
complex diagnostic features of COPD,56 our primary
aim was to use up-to-date survey data to evaluate differ-
ences in prevalence according to FT and LLN thresh-
olds, to provide baseline data for monitoring purposes
in the UK, and promote comparability with international
studies. Current recommendations regarding symptom
criteria are less speciﬁc than those for spirometry. We
chose, therefore, to examine the associations between
disease staging assessed only using spirometry and pres-
ence of respiratory symptoms, rather than broaden the
deﬁnition of disease.
Implications
Recent UK studies used administrative primary care
databases to report the number of diagnosed and
treated patients, thereby missing undiagnosed cases.
Such studies have reported prevalence below 2%.57 58
The disparity in prevalence from clinical versus epi-
demiological studies led to the development of the
COPD prevalence model, with the HSE 2001 used as
input data, to more accurately estimate prevalence.59 In
accordance with previous NICE recommendations,44
COPD is currently deﬁned in the model as FT stage II+
(FEV1/FVC <0.7 and FEV1 <80% of predicted), with the
logistic regression models showing sharp increases with
age and a modifying effect of gender.60 61 Similar to the
ﬁndings reported by Jordan et al,36 our study shows that
the strength of association between risk factors and
airﬂow obstruction varies according to spirometric criter-
ion, with age and sex differences in risk being more
marked for FT, and for FT stage II+, than LLN. In the
absence of agreement among experts, policymakers,
clinicians and researchers building the COPD epidemio-
logical database, it is important to appreciate the sensi-
tivity of estimates of the disease burden, and its
distribution across sociodemographic groups, to differ-
ences in methods, including spirometric cut-offs.
The prevalence of reported physician-diagnosed
COPD in our study was 2.8%, considerably lower
than spirometry-based estimates, possibly indicating
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considerable under-recognition by participants and phy-
sicians. Using the tightest deﬁnitions, prevalence of
physician-diagnosed COPD among participants with
obstructive spirometry was 30.2% (FT stage III+) and
14.7% (LLN stage II). Similar low rates of physician
diagnosis among participants meeting spirometric cri-
teria have been reported in New Zealand.62
Spirometrically deﬁned airﬂow obstruction but no diag-
nosed COPD does not necessarily indicate underdiagno-
sis. Deﬁnitive diagnosis requires further information on
all relevant clinical factors, particularly respiratory symp-
toms and smoking history, as well as postbronchodilator
spirometry.
CONCLUSION
In summary, we have enhanced the COPD epidemio-
logical database by evaluating the impact of different
deﬁnitions on the prevalence of potential airﬂow
obstruction and its associations with key risk factors and
comorbidities. With no gold standard currently available,
longitudinal studies examining differences in unsched-
uled hospital admissions and risk of death between FT
and LLN may inform the choice as to the best way to
include spirometric data in multidimensional assess-
ments of airﬂow obstruction in clinical and epidemio-
logical settings.
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